08:30 – 10:15
| | Brain Tumors I
|
08:30
| | From IDH1 to BRAF: Recent developments in the molecular
diagnostics of gliomas
A. von Deimling (Heidelberg)
|
09:05
| | Important issues with 1p 19q and MGMT methylation analysis
P. Collins (Cambridge/GB) |
09:40
IS–01
| | Non-stem cell origin for oligodendroglioma
W. Weiss (San Francisco, CA/US)
|
10:15 – 10:30 | | Kaffeepause
|
10:30 – 12:06 | | Brain Tumors II |
10:30
BT–04
| | Hypoxia upregulates Aldehyde dehydrogenase
Isoform 1 (ALDH1) expression and induces functional
stem cell characteristics in human glioblastoma cells
E. Soehngen, A. Schaefer, J. Koeritzer, V. Huelsmeyer,
J. Schlegel (Munich) |
10:42
BT–27
| | IDH1 mutation status defines more precisely than classical histology
distinct prognostic subgroups amon malignant astrocytomas
C. Hartmann, B. Hentschel, W. Wick, D. Capper, J. Felsberg, M. Simon,
M. Westphal, G. Schackert, R. Meyermann, T. Pietsch, G. Reifenberger,
M. Weller, M. Loeffler, A. von Deimling (Heidelberg)
|
10:54
BT–07
| | Detection of BRAF-KIAA1549 fusion transcript status
in pilocytic
astrocytomas using reverse transcription polymerasechain reaction
(RT-PCR) on formalin-fixed paraffin-embedded samples
M. Hasselblatt, B. Brokinkel, W. Stummer, W. Paulus (Münster)
|
11:06
BT–20
| | Characterization of immunohistochemical staining
patterns of an antibody specific for BRAF V600E
protein in primary and metastatic brain tumors
D. Capper (Heidelberg), M. Preusser (Heidelberg; Vienna/AT),
J. Schittenhelm (Tübingen), A. Jeibmann (Münster),
H. Zentgraf (Heidelberg), W. Paulus (Münster),
A. von Deimling (Heidelberg)
|
11:18
BT–12
| | The transcription factor EVI1 is involved in the
molecular pathogenesis of infratentorial
ependymomas
B. Koos (Münster), S. Gesk, R. Siebert (Kiel),
S. Bender, H. Witt (Heidelberg), S. Mertsch (Münster),
J. Felsberg (Düsseldorf), R. Beschorner (Tübingen),
A. Korshunov (Heidelberg), B. Riesmeier (Münster),
S. Pfister (Heidelberg), W. Paulus, M. Hasselblatt (Münster)
|
11:30
BT–21
| | The „go or grow“ potential of gliomas is linked to activity
of the neuropeptide processing enzyme carboxypeptidase
E (CPE)
P.N. Harter (Frankfurt a.M.), E. Höring, J. Seznec,
J. Schittenhelm, H.-J. Buehring, S. Bhattacharyya (Tübingen),
E. von Hattingen,
M. Mittelbronn (Frankfurt a.M.), U. Naumann (Tübingen)
|
11:42
BT–24
| | Targeting glioma cells with stemness properties
in vivo – limitations and perspectives
P.N. Harter, J. Weissenberger, P. Baumgarten,
E. Blank, P. Zeiner, J. Zinke, C. Zachskorn (Frankfurt a.M.),
R. Meyermann, J. Schittenhelm, H. Ohgaki (Tübingen),
M. Mittelbronn (Frankfurt a.M.) |
11:54
BT–40
| | Pituitary blastoma: a unique embryonal tumor
B. Scheithauer (Rochester, MN/US), E. Horvath (Toronto/CA),
T.W. Abel (Nashville, TN/US), Y. Robital (Montreal/CA),
S.-H. Park (Seoul/KR), R.Y. Osamura (Tokyo/JP), C. Deal (Montreal/CA),
R.V. Lloyd (Madison, WI/US), K. Kovacs (Toronto/CA) |
12:10 | | Posterbegehung Brain Tumors, Industrieausstellung, Mittagspause
|
13:20 – 14:10 | | Brain Tumors III
|
13:20
BT–17
| | Characterization of the Wnt/Wingless tumor suppressor gene WTX in
medulloblastoma and cerebellar tissue
E.-K. Wenzl, M. Regehly, K. Guse (Berlin), G. Röhn,
R. Goldbrunner (Cologne), W. Stenzel, U.W. Thomale
(Berlin), U. Schüller (Munich), F.L. Heppner, A. Koch (Berlin) |
13:32
BT–34
| | Nos2 deficiency leads to an increased incidence of medulloblastoma
in Ptch1+/- mice
P. Zipper (Düsseldorf), D. Haag (Heidelberg),
V. Westrich, D. Karra (Düsseldorf), K. Pfleger,
G. Toedt, F. Blond, N. Delhomme,
M. Hahn (Heidelberg), J. Reifenberger,
G. Reifenberger (Düsseldorf), P. Lichter (Heidelberg)
|
13:44
BT–29
| | Validation of histological and biological parameters for clinical
stratification of pediatric patients with standard risk medulloblastomas (SIOP-PNET 4 clinical trial): towards biology
T. Pietsch, S. Rutkowski (Germany), G. Gustafsson (Sweden),
D. Figarella-Branger (France), R. Kortmann (Germany), F. Doz (France),
B. Lannering (Sweden), D. Ellison (United States),
S. Clifford (United Kingdom) |
13:56
BT–06
| | Sensitivity of malignant peripheral nerve sheath
tumor cells to TRAIL depends on NF1 loss and IB
D. Reuss, J. Mucha, C. Hagenlocher (Heidelberg),
L. Kluwe (Heidelberg; Hamburg), V. Mautner (Hamburg),
A. von Deimling (Heidelberg)
|
14:10 – 14:20 | | Pause
|
14:20 – 15:42 | | Neuroimmunology I |
14:20
| | The Gut: Breeding Ground of MS
G. Krishnamoorthy (Martinsried)
|
14:55
| | Pathology and Pathogenesis of Immune Mediated Epilepsies
C.G. Bien (Bielefeld) |
15:30 – 16:00 | | Kaffeepause |
16:00 – 17:30 | | Neuroimmunology II
|
16:00
IS–03
| | Aß Immunotherapy for Alzheimer's disease:
Is it aiming at the right target?
J. Nicoll (Southampton/GB)
|
16:35
ND–11
| | Reducing Alzheimer's disease b-amyloid by
manipulating IL12/IL13 signalling
S. Prokop (Berlin), J. vom Berg, B. Becher (Zurich/CH),
R. Kälin, A. Wegner, F. Heppner (Berlin), F. Mair (Zurich/CH),
I. Lopategui-Cabezas (Havana/CU)
|
16:47 – 17:30 | | Poster Session Neuroimmunology
|
18:00 | | Mitgliederversammlung |
